Q-omics provides the consensus-scored CRPP1 profile across patient tissues and cancer cell-line models. CRPP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CRPP1 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, CRPP1 RNA expression shows 6,214 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight HNSC, LIHC, and COAD as cancer lineages where CRPP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRPP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRPP1 survival associations across molecular data types. CRPP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRPP1 RNA expression–survival associations across cancer types. High CRPP1 expression shows unfavorable associations in HNSC, KIRC, LUSC, THCA, KIRP and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CRPP1 RNA expression.
This table summarizes CRPP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CRPP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRPP1 shows lower tumor expression in LIHC. The LIHC box plot shows higher CRPP1 RNA expression in normal versus tumor tissue (log2 FC = −0.177, t-test p = .024).
This table shows molecular features associated with CRPP1 in patient tissues and cancer cell lines. In patient samples, CRPP1 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
